CA2874253A1 - 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease - Google Patents

7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease Download PDF

Info

Publication number
CA2874253A1
CA2874253A1 CA2874253A CA2874253A CA2874253A1 CA 2874253 A1 CA2874253 A1 CA 2874253A1 CA 2874253 A CA2874253 A CA 2874253A CA 2874253 A CA2874253 A CA 2874253A CA 2874253 A1 CA2874253 A1 CA 2874253A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
compound
optionally
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874253A
Other languages
English (en)
French (fr)
Inventor
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Stephen Cusack
Thibault Sauvaitre
Celine Michaut-Simon
Christophe Morice
Bruno Giethlen
Thierry Langer
Mark Smith
Sung-Sau So
Dirk Classen-Houben
Helmut Buschmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Savira Pharmaceuticals GmbH
Publication of CA2874253A1 publication Critical patent/CA2874253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2874253A 2012-05-23 2013-05-23 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease Abandoned CA2874253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650725P 2012-05-23 2012-05-23
US61/650,725 2012-05-23
PCT/EP2013/060634 WO2013174931A1 (en) 2012-05-23 2013-05-23 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
CA2874253A1 true CA2874253A1 (en) 2013-11-28

Family

ID=48669866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874253A Abandoned CA2874253A1 (en) 2012-05-23 2013-05-23 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease

Country Status (11)

Country Link
US (2) US20130317021A1 (zh)
EP (1) EP2861232A1 (zh)
JP (1) JP2015521189A (zh)
KR (1) KR20150014506A (zh)
CN (1) CN104507481B (zh)
BR (1) BR112014029006A2 (zh)
CA (1) CA2874253A1 (zh)
HK (1) HK1204987A1 (zh)
MX (1) MX2014014109A (zh)
RU (1) RU2014146778A (zh)
WO (1) WO2013174931A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
BR112014029016A8 (pt) * 2012-05-23 2018-01-09 European Molecular Biology Laboratory derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
HUE037371T2 (hu) 2012-12-07 2018-08-28 Vertex Pharma 2-Amino-6-fluor-N-(5-fluor-4-(4-(4-(oxetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il) pirazolo[1,5alfa]pirimidin-3-karboxamid mint ATR kináz inhibitor
CA2904760A1 (en) * 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
AU2014360380B2 (en) 2013-12-06 2019-03-21 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
SG11201610197XA (en) 2014-06-05 2017-01-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
DK3428170T3 (da) 2015-04-28 2021-03-01 Shionogi & Co Anti-influenza polycyklisk pyridonderivat og prodrug deraf
US20170081331A1 (en) 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
JP6323860B2 (ja) 2015-12-15 2018-05-16 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
WO2018001948A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
NZ750052A (en) 2016-08-10 2024-08-30 Shionogi & Co Ltd Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
US20200048259A1 (en) * 2016-10-12 2020-02-13 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018071283A1 (en) * 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
CR20200114A (es) 2017-09-15 2020-06-01 Aduro Biotech Inc Compuestos que contienen pirazolopirimidinona y sus usos
JP7305658B2 (ja) * 2018-01-31 2023-07-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
CN113620977B (zh) * 2021-08-24 2024-02-02 江苏弘和药物研发有限公司 一种噻唑烷并嘧啶酮乙酸的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2003101993A1 (en) * 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
EP1790638B1 (en) 2004-09-15 2013-04-03 Shionogi Co., Ltd. Carbamoylpyridone derivative having hiv integrase inhibitory activity
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
BR112014029016A8 (pt) * 2012-05-23 2018-01-09 European Molecular Biology Laboratory derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral

Also Published As

Publication number Publication date
BR112014029006A2 (pt) 2017-06-27
HK1204987A1 (zh) 2015-12-11
US20160367557A1 (en) 2016-12-22
JP2015521189A (ja) 2015-07-27
RU2014146778A (ru) 2016-07-10
CN104507481B (zh) 2017-08-04
US20130317021A1 (en) 2013-11-28
CN104507481A (zh) 2015-04-08
MX2014014109A (es) 2016-03-31
KR20150014506A (ko) 2015-02-06
WO2013174931A1 (en) 2013-11-28
EP2861232A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
EP2864338B1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
CA2874253A1 (en) 7-oxo-4,7-dihydro-pyrazolo [1,5-a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
US8921388B2 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2794616B1 (en) Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP3166951A1 (en) Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
US8952039B2 (en) Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease
CA2852750A1 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US9505758B2 (en) Substituted 1,5-naphthyridines as endonuclease inhibitors
WO2017046318A1 (en) Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
US20170081331A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
EP3166943A1 (en) Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza
WO2017046350A1 (en) Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190523